Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Several technologies for hemoglobinopathies are being transferred to commercial partners
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
New study presents a human-relevant stress model for assessing potential therapeutics
Subscribe To Our Newsletter & Stay Updated
